Plain-English translation of NCT06593431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding targeted local treatments—such as surgery, radiation therapy, or other focused procedures—to standard chemotherapy helps people with pancreatic cancer that has spread to a small number of spots (usually 1–5 locations). Right now, most patients with this type of cancer receive only chemotherapy. The trial wants to know if combining chemotherapy with procedures that directly target the visible tumors could help patients live longer and stay healthier.
Pancreatic cancer that spreads to only a few distant locations is different from cancer that spreads widely throughout the body. Researchers believe that treating all visible spots directly—in addition to chemotherapy—might give patients a better chance of longer survival, but this approach hasn't been proven in a large, rigorous study yet.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group will receive standard chemotherapy plus targeted treatments (surgery, radiation, or other procedures) aimed at all visible cancer spots, while the other group will receive chemotherapy alone. You will have imaging scans and blood tests throughout the trial to track how your cancer responds. The trial will follow you over time to measure how long you survive, when new tumors appear, and how the treatment affects your quality of life.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States